Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BCAB NASDAQ:CRIS NYSE:CVM NASDAQ:GMDA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCABBioAtla$0.35-5.0%$0.41$0.24▼$2.53$21.65M0.91906,919 shs1.38 million shsCRISCuris$1.80-2.2%$2.13$1.02▼$8.29$19.25M3.686,078 shs64,144 shsCVMCEL-SCI$3.96-5.0%$3.27$1.98▼$66.60$12.01M0.3205,141 shs417,623 shsGMDAGamida Cell$0.17$0.03▼$2.51$5.04M0.939.20 million shs23.04 million shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCABBioAtla-3.74%-4.14%-4.95%+14.45%-79.52%CRISCuris+2.22%-4.66%-22.03%+40.46%-72.25%CVMCEL-SCI+8.31%+9.16%+79.74%-45.45%-90.21%GMDAGamida Cell0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBCABBioAtla2.2325 of 5 stars3.31.00.00.02.72.50.6CRISCuris2.6089 of 5 stars3.54.00.00.02.70.00.6CVMCEL-SCI0.1683 of 5 stars0.02.00.00.01.40.00.6GMDAGamida CellN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCABBioAtla 2.50Moderate Buy$5.001,320.45% UpsideCRISCuris 3.00Buy$17.00844.44% UpsideCVMCEL-SCI 0.00N/AN/AN/AGMDAGamida Cell 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest GMDA, CVM, CRIS, and BCAB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/19/2025CRISCurisHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy$17.00(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCABBioAtla$11M1.87N/AN/A$0.25 per share1.41CRISCuris$10.91M1.73N/AN/A($0.71) per share-2.54CVMCEL-SCIN/AN/AN/AN/A$0.15 per shareN/AGMDAGamida Cell$1.78M0.00N/AN/A($0.02) per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCABBioAtla-$69.78M-$1.22N/AN/AN/AN/A-373.47%-116.55%8/6/2025 (Estimated)CRISCuris-$43.39M-$6.23N/AN/AN/A-376.08%N/A-97.14%7/30/2025 (Estimated)CVMCEL-SCI-$26.92M-$12.61N/AN/AN/AN/A-238.05%-104.65%N/AGMDAGamida Cell-$63M-$0.63N/AN/AN/AN/AN/A-57.59%N/ALatest GMDA, CVM, CRIS, and BCAB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025BCABBioAtla-$0.29N/AN/AN/AN/AN/A8/7/2025Q2 2025CRISCuris-$1.99N/AN/AN/AN/AN/A5/6/2025Q1 2025BCABBioAtla-$0.28-$0.29-$0.01-$0.26N/AN/A5/6/2025Q1 2025CRISCuris-$1.14-$1.25-$0.11-$1.25$2.37 million$2.38 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBCABBioAtlaN/AN/AN/AN/AN/ACRISCurisN/AN/AN/AN/AN/ACVMCEL-SCIN/AN/AN/AN/AN/AGMDAGamida CellN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCABBioAtlaN/A2.352.35CRISCurisN/A1.231.23CVMCEL-SCI0.661.071.09GMDAGamida Cell213.142.162.09Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCABBioAtla77.23%CRISCuris29.97%CVMCEL-SCI12.08%GMDAGamida Cell50.34%Insider OwnershipCompanyInsider OwnershipBCABBioAtla11.50%CRISCuris5.45%CVMCEL-SCI9.93%GMDAGamida Cell3.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCABBioAtla6058.42 million51.70 millionOptionableCRISCuris6010.46 million9.89 millionNo DataCVMCEL-SCI433.03 million64.67 millionOptionableGMDAGamida Cell143154.05 million143.70 millionOptionableGMDA, CVM, CRIS, and BCAB HeadlinesRecent News About These CompaniesGMDA to launch massive demolition drive against encroachments in GurugramNovember 7, 2024 | tribuneindia.comTOne week on, Gurgaon roads still riddled with craters, GMDA's claim rings hollowAugust 29, 2024 | timesofindia.indiatimes.comSunChip System from GamidaJuly 20, 2024 | news-medical.netNGamida Cell Announces New Leadership Under Ownership of Highbridge Capital ManagementJune 18, 2024 | businesswire.comGamida Cell files for U.S. bankruptcy as it undergoes restructuringApril 23, 2024 | bizjournals.comTwo Elbit Medical exit dreams punctured in a weekApril 4, 2024 | en.globes.co.ilEGamida Cell gets grant for method of preparing transplantable NK cell fraction for transplantationMarch 29, 2024 | pharmaceutical-technology.comPGoing private last option for Gamida Cell to remain as going concernMarch 28, 2024 | thepharmaletter.comTGamida Cell to delist as Highbridge takes full ownershipMarch 28, 2024 | en.globes.co.ilEQ4 2023 Gamida Cell Ltd Earnings CallMarch 28, 2024 | finance.yahoo.comGamida Cell, Ltd: Gamida Cell Announces Commencement of Restructuring Process Supported by Highbridge Capital ManagementMarch 27, 2024 | finanznachrichten.deGamida Cell, Ltd: Gamida Cell Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Company UpdateMarch 27, 2024 | finanznachrichten.deWhy Gamida Cell Shares Are Falling TodayMarch 27, 2024 | msn.comGMDA Stock Earnings: Gamida Cell Beats EPS, Beats Revenue for Q4 2023March 27, 2024 | investorplace.comWhy Is Gamida Cell (GMDA) Stock Down 82% Today?March 27, 2024 | investorplace.comGamida Cell GAAP EPS of $0.57 beats by $0.72, revenue of $1.78M beats by $0.72MMarch 27, 2024 | msn.comGamida Cell Annual Net Loss Narrows; To Be Taken PrivateMarch 27, 2024 | markets.businessinsider.comGamida Cell starts restructuring process supported by Highbridge Capital, stock downMarch 27, 2024 | msn.comGamida Cell Announces Commencement of Restructuring Process Supported by Highbridge Capital ManagementMarch 27, 2024 | globenewswire.comGamida Cell Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Company UpdateMarch 27, 2024 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir Soon3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military SpendIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI DefenseThe Ultimate Trump Bump: These Gov't Backed Stocks Are ExplodingBy Leo Miller | July 2, 2025View The Ultimate Trump Bump: These Gov't Backed Stocks Are ExplodingGMDA, CVM, CRIS, and BCAB Company DescriptionsBioAtla NASDAQ:BCAB$0.35 -0.02 (-5.02%) Closing price 04:00 PM EasternExtended Trading$0.36 +0.01 (+2.27%) As of 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody, which is in Phase II clinical trial for treating melanoma, carcinomas, and NSCLC; and BA3182, a bispecific candidate that is in Phase 1 study for the treatment of adenocarcinomas, as well as BA3361, which is in preclinical studies for treating multiple tumor types. The company was founded in 2007 and is headquartered in San Diego, California.Curis NASDAQ:CRIS$1.80 -0.04 (-2.17%) Closing price 04:00 PM EasternExtended Trading$1.79 -0.01 (-0.78%) As of 04:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreement with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed four programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.CEL-SCI NYSE:CVM$3.96 -0.21 (-5.04%) Closing price 04:00 PM EasternExtended Trading$3.97 +0.01 (+0.25%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers. It is also developing products based on its proprietary technology Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company's product pipeline includes CEL-2000; CEL-4000; and CEL-5000, which are LEAPS-based product candidates in preclinical trials for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.Gamida Cell NASDAQ:GMDAGamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious blood diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with hematologic malignancies, as well as in Phase II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, an investigational NK cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. The company was incorporated in 1998 and is headquartered in Jerusalem, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era How Goldman Sachs Earnings Help You Strategize Your Portfolio Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
